This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

This database contains 21 studies, archived under the term: "or"

Click here to filter this large number of results.

No Effect of Omega-3 Fatty Acid Supplementation on Cognition and Mood in Individuals with Cognitive Impairment and Probable Alzheimer’s Disease: A Randomised Controlled Trial

Findings from epidemiological and observational studies have indicated that diets high in omega-3 polyunsaturated fatty acids (PUFAs) such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) may reduce the risk of cognitive decline and Alzheimer’s disease (AD). To determine if increasing intake of DHA and EPA through supplementation is beneficial to cognition and mood in […]

Relapse risk after discontinuation of risperidone in Alzheimer’s disease

Background: Among patients with Alzheimer’s disease who have had a response to antipsychotic medication for psychosis or agitation-aggression, the risk of a recurrence of symptoms after discontinuation of the medication has not been established.; Methods: Patients with Alzheimer’s disease and psychosis or agitation-aggression received open-label treatment with risperidone for 16 weeks. Those who had a […]

Effect of second-generation antipsychotics on caregiver burden in Alzheimer’s disease

Background: Alzheimer’s disease (AD) imposes a severe burden upon patients and their caregivers. Severity of psychiatric symptoms and behavioral disturbances is an important determinant of caregivers’ experience of burden. These symptoms may be improved with atypical antipsychotic treatment.; Objective: Data from the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer’s Disease (CATIE-AD) trial were used to evaluate […]

Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer’s disease cohort

Background: Activities of daily living (ADL) are an essential part of the diagnostic criteria for Alzheimer’s disease (AD). A decline in ADL affects independent living and has a strong negative impact on caregiver burden. Functional response to cholinesterase inhibitor (ChEI) treatment and factors that might influence this response in naturalistic AD patients need investigating. The […]

Two galantamine titration regimens in patients switched from donepezil

Objectives: In addition to inhibiting acetylcholinesterase, galantamine has allosteric-modulating activity at nicotinic receptors. This may make galantamine an attractive option for patients starting treatment for Alzheimer’s disease (AD), but also for those who have not benefited from their current therapy. This study explored outcomes in subjects with AD transitioning from donepezil because of insufficient tolerability […]

Discontinuation of antidepressants in people with dementia and neuropsychiatric symptoms (DESEP study): double blind, randomised, parallel group, placebo controlled trial

Objective: To determine the effect of discontinuing antidepressant treatment in people with dementia and neuropsychiatric symptoms.; Design: Double blind, randomised, parallel group, placebo controlled trial.; Setting: Norwegian nursing homes; residents recruited by 16 study centres in Norway from August 2008 to June 2010.; Participants: 128 patients with Alzheimer’s disease, dementia or vascular dementia, and neuropsychiatric […]

Optimised anaesthesia to reduce post operative cognitive decline (POCD) in older patients undergoing elective surgery, a randomised controlled trial

Background: The study determined the one year incidence of post operative cognitive decline (POCD) and evaluated the effectiveness of an intra-operative anaesthetic intervention in reducing post-operative cognitive impairment in older adults (over 60 years of age) undergoing elective orthopaedic or abdominal surgery.; Methods and Trial Design: The design was a prospective cohort study with a […]

Public-private partnerships improve health outcomes in individuals with early stage Alzheimer’s disease

Purpose: In a collaborative effort between the Missouri Department of Health, Area Agencies on Aging (AAA), Alzheimer Association, and academic researchers, we tested whether early dementia detection and comprehensive care consultations would improve health outcomes in care receivers (CRs) and their family caregivers (FCGs), therefore addressing an important public health concern.; Participants and Methods: A […]

Extended results of the Alzheimer’s disease anti-inflammatory prevention trial

Background: Epidemiologic evidence suggests that nonsteroidal anti-inflammatory drugs (NSAIDs) delay onset of Alzheimer’s dementia (AD), but randomized trials show no benefit from NSAIDs in patients with symptomatic AD. The Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT) randomized 2,528 elderly persons to naproxen or celecoxib versus placebo for 2 years (standard deviation = 11 months) before treatments […]

Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin

To determine incidence of dementia in type 2 diabetic (T2DM) patients, and whether there are adverse or favorable effects of oral agents (OA) in DM, we obtained a representative cohort of 800,000 from Taiwan’s National Health Insurance database. Those who, as of on January 1, 2000, were 50 years or older and dementia free (n […]

Try searching our database by another keyword...

To make a new query of the database, please enter your search terms below: